Evkeeza mechanism of action?

What is Evkeeza, and what does it do in the body?

Evkeeza (evinacumab) is a monoclonal antibody used to lower blood cholesterol in people with certain inherited lipid disorders. Its mechanism targets a specific liver process involved in cholesterol clearance. [1][2]

How does evinacumab work at the molecular level?

Evinacumab binds to angiopoietin-like 3 (ANGPTL3). By blocking ANGPTL3, it enhances lipid metabolism pathways that reduce circulating lipoproteins, including low-density lipoprotein cholesterol (LDL-C), even when LDL receptor function is limited. [1]

Why can Evkeeza lower LDL cholesterol even without normal LDL receptors?

Evkeeza’s ANGPTL3 blockade shifts lipid processing in a way that does not rely on LDL receptors to the same extent as many older LDL-lowering therapies. This is why it can be effective in patients with familial hypercholesterolemia, including those who have limited LDL receptor activity. [1][2]

Which patients are typically treated with Evkeeza based on how it works?

Evkeeza is used for inherited forms of high cholesterol, where ANGPTL3-driven lipid regulation plays a key role. Its LDL-reducing action via ANGPTL3 inhibition is a central reason it is prescribed for these genetic conditions. [2]

What outcomes should be expected from the mechanism?

Because Evkeeza acts upstream by modulating lipid metabolism through ANGPTL3, it lowers LDL-C and other related lipid measures rather than acting directly on the gut to reduce cholesterol absorption or directly inhibiting cholesterol synthesis pathways. [1][2]

Sources

1. Evkeeza (evinacumab-dgnb) prescribing information (FDA)
   
2. Evkeeza overview and mechanism of action (NHS/other clinical resource)